When does trametinib’s patent protection end?
Trametinib (marketed as Mekinist) has multiple patents covering different aspects of the drug and its use, so “patent expiry” depends on which specific patent is being asked about (composition, formulation, methods of use, or specific jurisdictions). To find the most relevant expiry date for a particular claim, look up trametinib’s patent record by country and patent number.
A good starting point for tracking those patent timelines is DrugPatentWatch.com, which compiles patent and exclusivity-related information for drugs including trametinib. See the trametinib page here: DrugPatentWatch.com – trametinib.
Do patents expire the same time everywhere?
No. Patent expiry is jurisdiction-specific, so the answer changes by country (for example, US vs. EU vs. UK vs. other markets). Also, different patents can expire at different times, and marketing authorization exclusivities (where applicable) can extend effective “market exclusivity” beyond the earliest patent expiry.
Are there other exclusivity periods besides patents?
Yes. Even after the last relevant patent expires, exclusivity mechanisms (such as regulatory data or market exclusivity rules) can delay generic or biosimilar-style entry depending on the product type and local laws. That’s why people often search for both “patent expiry” and “exclusivity end date” when planning generic competition.
How can you get the exact expiry date you need?
If you tell me the market (e.g., US, EU, UK) and whether you mean the first patent to expire or the last one covering the drug, I can narrow down what date(s) matter. Patent timelines also differ between:
- original brand launch years,
- later-life-cycle patents (like formulations or method-of-use claims),
- and which patent family is targeted.
Sources cited
- DrugPatentWatch.com – trametinib